Urocortin

Overview

Urocortin (also called urocortin 1 or Ucn1) is a 40-amino acid neuropeptide belonging to the corticotropin-releasing factor (CRF) family. It was discovered in 1995 by Vaughan and colleagues at the Salk Institute, isolated from rat brain. The name derives from its structural similarity to fish urotensin I and mammalian CRF (corticotropin-releasing factor/hormone). Urocortin shares approximately 45% sequence identity with CRF and binds both CRF receptor subtypes, but with a notably different affinity profile: while CRF preferentially activates CRF1, urocortin has high affinity for both CRF1 and CRF2 receptors, with approximately 40-fold greater affinity for CRF2 than CRF itself.

Two additional family members were subsequently discovered: urocortin 2 (stresscopin-related peptide) and urocortin 3 (stresscopin), both of which are selective CRF2 agonists. The existence of multiple CRF-family peptides with different receptor selectivity profiles suggests the stress response system is more nuanced than a simple CRF-driven activation.

Urocortin has attracted particular interest for two reasons beyond stress biology. First, it has potent cardiovascular effects, increasing cardiac output and inducing vasodilation — properties that have been investigated in heart failure. Second, it appears to function as an anxiolytic and stress-coping signal, distinct from the stress-activating properties typically associated with CRF itself.

Amino Acid Sequence

Human urocortin 1: DNPSLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSV-NH₂

• Molecular weight: ~4,696 g/mol
• Gene: UCN (chromosome 2p23.3)
• CAS Number: 178564-05-3
• Receptors: CRF1 (high affinity), CRF2 (high affinity)

Structural features:

• Alpha-helical C-terminal domain — required for receptor binding; the helical segment contacts the extracellular domain of CRF receptors
• C-terminal amidation — enhances receptor affinity and protease resistance
• 45% homology with CRF — sufficient for shared receptor binding but with distinct selectivity
• 40-fold higher CRF2 affinity than CRF — this enhanced CRF2 engagement drives urocortin's distinctive cardiovascular and anxiolytic pharmacology

Mechanism of Action

Receptor Pharmacology

The CRF receptor system consists of two GPCRs:

CRF1 Receptor:

• Widely expressed in brain (cortex, hippocampus, amygdala, cerebellum) and pituitary
• Mediates the classical stress response: ACTH release, anxiety, arousal
• Urocortin activates CRF1 with slightly higher affinity than CRF itself

CRF2 Receptor:

• Expressed in brain (lateral septum, ventromedial hypothalamus, dorsal raphe), heart, skeletal muscle, and gastrointestinal tract
• Mediates stress recovery, anxiolysis, appetite suppression, and cardiovascular effects
• Urocortin is considered the primary endogenous CRF2 ligand

Both receptors couple to Gs, activating adenylyl cyclase and increasing cAMP/PKA signaling. CRF2 can also couple to other G proteins in a tissue-dependent manner.

Stress and Anxiety

• Urocortin activates CRF2 in brain regions associated with stress coping rather than stress initiation
• CRF2 activation in the lateral septum produces anxiolytic effects
• Urocortin may represent a stress-recovery signal: while CRF initiates the stress response via CRF1, urocortin and its relatives signal through CRF2 to promote adaptation and recovery
• CRF-binding protein (CRF-BP) sequesters both CRF and urocortin, providing a buffer mechanism

Cardiovascular Effects

Urocortin produces pronounced cardiovascular effects through CRF2 activation:

• Positive inotropy — increases cardiac contractility without increasing oxygen demand
• Vasodilation — reduces systemic vascular resistance
• Cardioprotection — reduces infarct size in ischemia-reperfusion models
• Anti-hypertrophic — inhibits pathological cardiac remodeling
• These effects are mediated by CRF2 receptors on cardiomyocytes and vascular smooth muscle, activating cAMP/PKA and PI3K/Akt survival pathways

Appetite Suppression

• Central urocortin potently suppresses food intake, primarily via CRF2 in the ventromedial hypothalamus and parabrachial nucleus
• More potent anorectic effect than CRF at equivalent doses
• Distinguished from CRF-induced anorexia by lacking the aversive/stress component

Research Summary

Pharmacokinetics

• Half-life: Approximately 10-12 minutes in plasma
• Metabolism: Degraded by endopeptidases; CRF-binding protein (CRF-BP) binds and modulates availability
• Route (research): Intravenous (cardiovascular studies), intracerebroventricular (behavioral studies)
• Expression: Brain (Edinger-Westphal nucleus is the primary CNS source), heart, gut, immune cells, placenta
• Circulating levels: Low; functions primarily as a local paracrine/autocrine factor

CRF Family Comparison

Common Discussion Topics

1. Stress initiation vs. stress recovery — The CRF/CRF1 system initiates the stress response, while the urocortin/CRF2 system promotes adaptation and recovery. This framework helps explain paradoxical findings where CRF family peptides produce both anxiogenic and anxiolytic effects.

2. Heart failure therapeutic potential — Small clinical trials have shown urocortin infusion improves hemodynamics in heart failure patients. The combination of inotropy without increased oxygen demand and vasodilation makes it pharmacologically attractive, but peptide delivery challenges have limited development.

3. Anti-atrophy applications — CRF2 activation by urocortin 2 prevents muscle atrophy in animal models, connecting stress biology to musculoskeletal research and potentially to conditions like sarcopenia and cachexia.

4. Appetite regulation — Urocortin's potent anorexic effect through CRF2 has generated interest in metabolic disease, though separating the appetite-suppressing effects from other CRF system actions remains a drug development challenge.

5. Gastrointestinal effects — Urocortin modulates gut motility and inflammation, connecting the CRF system to the gut-brain axis and inflammatory bowel disease research.

Related Compounds

• Substance P — neuropeptide involved in stress and pain signaling through different pathways
• Neuropeptide Y — stress-responsive neuropeptide with opposing anxiolytic and orexigenic effects
• Orexin-A — wakefulness neuropeptide with arousal-stress integration
• Adrenomedullin — vasodilatory peptide with complementary cardiovascular protective effects
• Galanin — neuropeptide involved in stress, mood, and feeding regulation